Forest Labs (FRX) shares are -7.5% after it cuts its FY 2013 EPS guidance to $0.65-$0.80, well below consensus of $1. Forest Labs cited sharply lower-than-expected sales of its Lexapro treatment following the expiration of the drug's patent in March this year.
More Stocks News
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com
More Stocks News
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com